相似文献
1
Cancer and fertility preservation: fertility preservation in breast cancer patients.
Breast Cancer Res. 2008;10(2):206. doi: 10.1186/bcr1991. Epub 2008 Apr 29.
2
[Breast cancer and fertility: critical review, considerations and perspectives].
Bull Cancer. 2008 Jan;95(1):17-25. doi: 10.1684/bdc.2007.0496.
3
Fertility after breast cancer treatment.
Eur J Obstet Gynecol Reprod Biol. 2014 Feb;173:13-8. doi: 10.1016/j.ejogrb.2013.11.009. Epub 2013 Nov 17.
4
Impact of breast cancer treatment on fertility.
Breast Cancer Res Treat. 2010 Sep;123 Suppl 1:59-63. doi: 10.1007/s10549-010-1069-7. Epub 2010 Aug 14.
5
Techniques for fertility preservation in patients with breast cancer.
Curr Opin Obstet Gynecol. 2009 Feb;21(1):68-73. doi: 10.1097/GCO.0b013e32831e13b9.
6
Fertility preservation for breast cancer patients.
Semin Reprod Med. 2009 Nov;27(6):486-92. doi: 10.1055/s-0029-1241059. Epub 2009 Oct 5.
7
Fertility preservation options in breast cancer patients.
Gynecol Endocrinol. 2015;31(11):846-51. doi: 10.3109/09513590.2015.1081684. Epub 2015 Sep 15.
8
Preservation of fertility and the impact of subsequent pregnancy in patients with premenopausal breast cancer.
Semin Oncol. 2006 Dec;33(6):664-71. doi: 10.1053/j.seminoncol.2006.08.015.
9
Fertility and adjuvant treatment in young women with breast cancer.
Breast. 2007 Dec;16 Suppl 2:S175-81. doi: 10.1016/j.breast.2007.07.029. Epub 2007 Sep 4.
10
Assisted reproduction and breast cancer.
Minerva Ginecol. 2007 Aug;59(4):403-14.
引用本文的文献
1
Targeted Hyperbranched Nanoparticles for Delivery of Doxorubicin in Breast Cancer Brain Metastasis.
Mol Pharm. 2023 Dec 4;20(12):6169-6183. doi: 10.1021/acs.molpharmaceut.3c00558. Epub 2023 Nov 16.
2
Isoform-Specific Roles of Mutant p63 in Human Diseases.
Cancers (Basel). 2021 Jan 31;13(3):536. doi: 10.3390/cancers13030536.
3
After cyclophosphamide exposure, granulosa cells recover their anti-müllerian hormone-producing ability but not their numbers.
Cytometry A. 2021 Aug;99(8):807-813. doi: 10.1002/cyto.a.24297. Epub 2020 Dec 30.
4
DNA Damaged Induced Cell Death in Oocytes.
Molecules. 2020 Dec 3;25(23):5714. doi: 10.3390/molecules25235714.
5
Practical consensus recommendations on fertility preservation in patients with breast cancer.
South Asian J Cancer. 2018 Apr-Jun;7(2):110-114. doi: 10.4103/sajc.sajc_113_18.
6
The positive effect of a dedicated adolescent and young adult fertility program on the rates of documentation of therapy-associated infertility risk and fertility preservation options.
Support Care Cancer. 2017 Jun;25(6):1915-1922. doi: 10.1007/s00520-017-3597-8. Epub 2017 Feb 2.
7
The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients.
Oncotarget. 2017 Feb 14;8(7):11372-11379. doi: 10.18632/oncotarget.14532.
8
If you did not document it, it did not happen: rates of documentation of discussion of infertility risk in adolescent and young adult oncology patients' medical records.
J Oncol Pract. 2015 Mar;11(2):137-44. doi: 10.1200/JOP.2014.000786. Epub 2014 Dec 30.
9
Current evidence supporting "letrozole" for ovulation induction.
J Hum Reprod Sci. 2013 Apr;6(2):93-8. doi: 10.4103/0974-1208.117166.
10
Management of reproductive health in Cowden syndrome complicated by endometrial polyps and breast cancer.
Obstet Gynecol. 2013 Feb;121(2 Pt 2 Suppl 1):461-464.
本文引用的文献
1
Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury.
Oncologist. 2007 Sep;12(9):1055-66. doi: 10.1634/theoncologist.12-9-1055.
2
How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries.
Oncologist. 2007 Sep;12(9):1044-54. doi: 10.1634/theoncologist.12-9-1044.
3
Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC).
Breast Cancer Res Treat. 2008 Aug;110(3):411-6. doi: 10.1007/s10549-007-9745-y. Epub 2007 Sep 13.
4
Fertility and adjuvant treatment in young women with breast cancer.
Breast. 2007 Dec;16 Suppl 2:S175-81. doi: 10.1016/j.breast.2007.07.029. Epub 2007 Sep 4.
5
6
Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
Lancet. 2007 May 19;369(9574):1711-23. doi: 10.1016/S0140-6736(07)60778-8.
7
Controversies in preservation of ovary function and fertility in patients with breast cancer.
Breast Cancer Res Treat. 2008 Mar;108(1):1-7. doi: 10.1007/s10549-007-9572-1. Epub 2007 Apr 25.
8
The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane.
Am J Clin Oncol. 2007 Apr;30(2):126-32. doi: 10.1097/01.coc.0000251398.57630.4f.
9
Relative potencies of anastrozole and letrozole to suppress estradiol in breast cancer patients undergoing ovarian stimulation before in vitro fertilization.
J Clin Endocrinol Metab. 2007 Jun;92(6):2197-200. doi: 10.1210/jc.2007-0247. Epub 2007 Mar 13.
10
The effect of a GnRH agonist on cryopreserved human ovarian grafts in severe combined immunodeficient mice.
Reproduction. 2007 Feb;133(2):503-9. doi: 10.1530/REP-06-0061.
Zotero 插件